Get the Stockscreener App
0.3105
1.65%
-0.0052
After Hours:
.32
0.0095
+3.06%
Vyne Therapeutics Inc stock is traded at $0.3105, with a volume of 1.17M.
It is down -1.65% in the last 24 hours and down -10.65% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$0.3157
Open:
$0.316
24h Volume:
1.17M
Relative Volume:
0.55
Market Cap:
$7.91M
Revenue:
$486.00K
Net Income/Loss:
$-28.43M
P/E Ratio:
-0.1101
EPS:
-2.8189
Net Cash Flow:
$-26.75M
1W Performance:
+3.78%
1M Performance:
-10.65%
6M Performance:
-83.22%
1Y Performance:
-82.65%
1-Day Range:
$0.30
$0.3177
1-Week Range:
$0.2805
$0.3299
52-Week Range:
$0.2805
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.3105 | 7.82M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
VYNE Therapeutics Inc. stock outlook for YEARJuly 2025 WrapUp & Entry Point Strategy Guides - Newser
Trend analysis for VYNE Therapeutics Inc. this weekBuy Signal & High Accuracy Buy Signal Tips - Newser
VYNE Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Ranking VYNE Therapeutics Inc. among high performing stocks via toolsFed Meeting & Weekly Momentum Picks - Newser
What moving averages say about VYNE Therapeutics Inc.2025 Top Decliners & Entry Point Confirmation Alerts - Newser
Analyzing recovery setups for VYNE Therapeutics Inc. investorsJuly 2025 Retail & Risk Adjusted Buy/Sell Alerts - Newser
Using economic indicators to assess VYNE Therapeutics Inc. potentialMarket Growth Report & Expert Approved Momentum Trade Ideas - Newser
News impact scoring models applied to VYNE Therapeutics Inc.July 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Candlestick signals on VYNE Therapeutics Inc. stock todayEarnings Miss & Real-Time Sentiment Analysis - Newser
Is VYNE Therapeutics Inc. stock poised for growthPortfolio Gains Summary & Community Consensus Picks - Newser
Key resistance and support levels for VYNE Therapeutics Inc.2025 Historical Comparison & AI Driven Stock Movement Reports - Newser
How to interpret RSI for VYNE Therapeutics Inc. stock2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Chart overlay techniques for tracking VYNE Therapeutics Inc.Earnings Recap Report & Weekly Watchlist for Consistent Profits - Newser
Institutional scanner results for VYNE Therapeutics Inc.July 2025 Decliners & Weekly Top Performers Watchlists - Newser
Technical analysis overview for VYNE Therapeutics Inc. stock2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - Newser
VYNE Therapeutics Inc. stock momentum explainedWeekly Market Report & High Yield Stock Recommendations - Newser
Is VYNE Therapeutics Inc. reversing from oversold territoryVolume Spike & Weekly Breakout Watchlists - Newser
vyne therapeutics inc. stock outlook for yearWeekly Gains Report & Daily Oversold Bounce Ideas - Newser
Why VYNE Therapeutics Inc. is moving todayIndex Update & Low Risk High Reward Ideas - Newser
Will VYNE Therapeutics Inc. price bounce be sustainable2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Using data models to predict VYNE Therapeutics Inc. stock movementMarket Sentiment Summary & AI Optimized Trading Strategy Guides - Newser
Is VYNE Therapeutics Inc. stock showing strong momentumJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - Lancaster City Council
How to manage a losing position in VYNE Therapeutics Inc.2025 Key Lessons & Technical Pattern Based Signals - Newser
What to do if you’re stuck in VYNE Therapeutics Inc.July 2025 Drop Watch & Daily Market Momentum Tracking - Newser
Is it time to cut losses on VYNE Therapeutics Inc.2025 Trading Volume Trends & Real-Time Volume Spike Alerts - Newser
ranking vyne therapeutics inc. among high performing stocks via toolsJuly 2025 Technicals & Real-Time Volume Triggers - Newser
Price action breakdown for VYNE Therapeutics Inc.Portfolio Gains Report & Low Risk High Win Rate Stock Picks - Newser
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):